Abiomed - ABMD Stock Forecast, Price & News

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

Abiomed Trading Up 0.5 %

Shares of NASDAQ:ABMD opened at $295.06 on Tuesday. Abiomed has a twelve month low of $219.85 and a twelve month high of $379.30. The stock has a fifty day simple moving average of $265.75 and a 200-day simple moving average of $282.87. The stock has a market capitalization of $13.46 billion, a PE ratio of 62.25 and a beta of 1.35.

Abiomed (NASDAQ:ABMD - Get Rating) last issued its quarterly earnings data on Thursday, August 4th. The medical equipment provider reported $1.25 earnings per share for the quarter, beating analysts' consensus estimates of $1.06 by $0.19. Abiomed had a return on equity of 14.33% and a net margin of 20.60%. The business had revenue of $277.15 million during the quarter, compared to analysts' expectations of $276.46 million. During the same period in the previous year, the firm posted $1.10 earnings per share. The company's revenue was up 9.7% on a year-over-year basis. On average, equities analysts predict that Abiomed will post 4.73 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ABMD. StockNews.com downgraded Abiomed from a "buy" rating to a "hold" rating in a research report on Friday, July 1st. Deutsche Bank Aktiengesellschaft cut their target price on Abiomed from $410.00 to $355.00 in a research note on Thursday, July 21st. Finally, Morgan Stanley cut their target price on Abiomed from $275.00 to $235.00 and set an "underweight" rating for the company in a research note on Friday, July 15th.

Insider Activity

In other news, CFO Todd A. Trapp sold 1,000 shares of Abiomed stock in a transaction on Wednesday, August 3rd. The stock was sold at an average price of $300.00, for a total value of $300,000.00. Following the completion of the sale, the chief financial officer now directly owns 16,927 shares of the company's stock, valued at $5,078,100. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 2.50% of the company's stock.